MBX Biosciences Inc. Comm...

AI Score

0

Unlock

10.34
-2.00 (-16.21%)
At close: Feb 10, 2025, 3:59 PM
10.26
-0.77%
After-hours Feb 10, 2025, 04:00 PM EST
undefined%
Bid 7
Market Cap 345.54M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.65
PE Ratio (ttm) -6.27
Forward PE n/a
Analyst Buy
Ask 12
Volume 710,960
Avg. Volume (20D) 274,701
Open 12.85
Previous Close 12.34
Day's Range 8.63 - 12.86
52-Week Range 8.63 - 27.50
Beta undefined

About MBX

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developi...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 14, 2000
Employees 38
Stock Exchange NASDAQ
Ticker Symbol MBX

Analyst Forecast

According to 4 analyst ratings, the average rating for MBX stock is "Buy." The 12-month stock price forecast is $37.5, which is an increase of 262.67% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 months ago
+4.05%
MBX Biosciences shares are trading higher. The sto... Unlock content with Pro Subscription